British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

Blog - A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

July is Chronic Disease Awareness Month and while many people believe RSV affects only infants and young children, the ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

Public Health – Seattle and King County has seen an increase in emergency visits for COVID-19 over the last month, although ...

As FDA kicked off the drug user fee reauthorization process, Commissioner Marty Makary said he’d like to see lower fees paid ...

Indian pediatric experts report that Respiratory Syncytial Virus (RSV) causes a significant number of infant respiratory ...

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...